Non-steroidal anti-inflammatory drugs and melanoma

Current Pharmaceutical Design

Volumn 18, Issue 26, 2012, Pages 3966-3978

  Sanz Motilva, Virginia ^a   Martorell Calatayud, Antonio ^b   Nagore, Eduardo ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL DE MANISES   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Melanoma; Non steroidal anti inflammatory drugs; Prevention; Risk; Therapy

Indexed keywords

ARSENIC; ASBESTOS; CELECOXIB; CIGARETTE SMOKE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; LIPOXIN A; LIPOXIN B; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SILICON DIOXIDE; THROMBOXANE A2; TREOSULFAN; VASCULOTROPIN; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; COLON CANCER; CONTINUOUS INFUSION; DISEASE COURSE; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFLAMMATION; INTESTINE FLORA; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT LENTIGO; MELANOMA; MERKEL CELL TUMOR; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOMA; STOMACH CANCER; TREATMENT DURATION; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 84864538653     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802083680     Document Type: Review

References (163)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
3. Prendergast GC, Metz R, Muller AJ. Towards a Genetic Definition of Cancer-associated inflammation. Am J Pathol 2010; 176: 2082-7
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2002; 357: 539-45.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
6. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-83.
7. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003; 3: 276-85.
8. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004; 432: 324-31.
9. Houchen CW, Stenson WF, Cohn SM. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am J Physiol Gastrointest Liver Physiol 2000; 279: G858-65.
10. Morteau O, Morham SG, Sellon R, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105: 469-78.
11. Brown SL, Riehl TE, Walker MR, et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 2007; 117: 258-69.
12. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
13. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-8.
14. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science 1985; 230: 676-8.
15. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990; 248: 1656-60.
16. SiewekeMH, StokerAW, BissellMJ. Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis. Cancer Res 1989; 49: 6419-24.
17. Martins-Green M, Boudreau N, Bissell MJ. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 1994; 54: 4334-41.
18. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998; 133: 383-9.
19. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
20. Egan LJ, Eckmann L, Greten FR, et al. IkappaB-kinasebetadependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004; 101: 2452-7.
21. Chae S, Eckmann L, Miyamoto Y, Pothoulakis C, Karin M, Kagnoff MF. Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. J Immunol 2006; 177: 1214-20.
22. Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 1999; 163: 1457-66.
23. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
24. Rakoff-Nahoum S. Why cancer and inflammation? Yale J biol med 2006; 79: 123-30.
25. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.
26. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
27. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficientmice. Science 1996; 274: 1379-83.
28. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Nature 2006; 441: 431-6.
29. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
30. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
31. MuellerMM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-49.
32. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-90.
33. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
34. Hull MA, Booth JK, Tisbury A, et al. Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-405.
35. SonoshitaM, Takaku K, OshimaM, Sugihara K, TaketoMM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002; 62: 6846-9.
36. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254-7.
37. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000; 60: 2562-6.
38. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-11.
39. Opdenakker G, Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 2004; 48: 519-27.
40. Guan Y, Zhang Y, Schneider A, et al. Urogenital distribution of a mouse membrane-associated prostaglandin E(2) synthase. Am J Physiol Renal Physiol 2001; 281: F1173-7.
41. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-29.
42. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226.
43. Versteeg HH, van Bergen en Henegouwen PM, van Deventer SJ, Peppelenbosch MP. Cyclooxygenase-dependent signalling: molecular events and consequences. FEBS Lett 1999; 445: 1-5.
44. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull 1987; 43: 285-96.
45. Chan SC, Kim JW, Henderson WR Jr, Hanifin JM. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1993; 151: 3345-52.
46. Moncada S, Vane JR. Prostacyclin and the vascular endothelium. Bull Eur Physiopathol Respir 1981; 17: 687-701.
47. Dowd PM, Kobza Black A, Woollard PM et al. Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE). J Invest Dermatol 1985; 84: 537-41.
48. Gualde N, Atluru D, Goodwin JS. Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets. J Immunol 1985; 134: 1125-9.
49. Vanderhoek JY, Bryant RW, Bailey JM. 15-hydroxy-5,8,11,13-eicosatetraenoic acid: a potent and selective inhibitor of platelet lipoxygenase. J Biol Chem 1980; 255: 5996-8.
50. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
51. Miyaura C, Inada M, Suzawa T, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000; 275: 19819-23.
52. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000; 287: 2013-7.
53. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23.
54. Yopp AC, Randolph GJ, Bromberg JS. Leukotrienes, sphingolipids, and leukocyte trafficking. J Immunol 2003; 171: 5-10.
55. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
56. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to infl amed tissues. Nat Immunol 2003; 4: 965-73.
57. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate immunoglobulin Edependent cysteinyl leukotriene production by human cord bloodderived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 2001; 193:123-33.
58. Ott VL, Cambier JC, Kappler J et al. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003; 4: 974-81.
59. Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4: 982-90.
60. Nigam S, Fiore S, Luscinskas FW, Serhan CN. Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between lipid remodeling and adhesion. J Cell Physiol 1990; 143: 512-23.
61. Fiore S, Ryeom SW, Weller PF, Serhan CN. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem 1992; 267: 16168-76.
62. Khshivo AL, Nekrasov AS, Lankin VZ, Kholodov AIu, Vikhert AM, Popov GK. [Lipoxin B, an enhancing factor of spontaneous platelet aggregation in whole blood.] Biull Eksp Biol Med 1989; 108: 26-8.
63. Beckman BS, Despinasse BP, Spriggs L. Actions of lipoxins A4 and B4 on signal transduction events in Friend erythroleukemia cells. Proc Soc Exp Biol Med 1992; 201: 169-73.
64. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 1996; 183: 137-46.
65. Stenke L, Edenius C, Samuelsson J, Lindgren JA. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2989-95.
66. Brink C. Leukotriene receptors: state of the art. Adv Exp Med Biol 2003; 525: 7-10.
67. Drazen JM. Anti-leukotrienes as novel anti-inflammatory treatments in asthma. Adv Exp Med Biol 2002; 507: 217-21.
68. Newton Bishop, J. A. Lentigos, Melanocytic Naevi and Melanoma. In: Burns T, Breathnach S., Cox N., Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell;2010. p. 54.32-56.
69. Nestle FO, Kerl H. Melanoma. In: Bolognia J, Jorizzo JL, Rapini RP, editors. Dermatologia. Madrid:Elsevier;2004. p. 1789-815.
70. Paek SC, Sober AJ, Tsao H, Mihm MC, Johnson TM. Cutaneous melanoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ. Fitzpatricḱs dermatology in general medicine. New York: Mc Graw-Hil;2008. p. 1134-57
71. Elder DE, Murphy GF. Melanocytic Tumors of the Skin. Washington, DC: American Registry of Pathology, in press.
72. Baumert J, Plewig G, Volkenandt M, Schmid-Wendtner MH. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007; 156: 938-44.
73. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/ lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg 2006; 32: 493-504.
74. Breslow A. Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol 1979; 6: 208-12.
75. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
76. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2005; 23: 8065-75.
77. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-34.
78. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22: 3668-76.
79. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048-56.
80. Chun KS, Surth YJ. Signal transduction pathways regulating cyclooxigenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004; 68: 1089-100.
81. Chiu LC, Tong KF. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother; 2005: 59 Suppl 2: S293-7.
82. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: Review and preview. J Cutan Med Surg 2002; 6: 449-59.
83. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
84. Tsujii M, Dubois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overespressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
85. Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991; 3: 1-7.
86. Leihr J, Wang M. Lipid hydroperoxide-induced endogenous DNA adducts in hamsters: Possible mechanisms of lipid hydroperoxidemediated carcinogenesis. Arch Biochem Biophys 1995; 316: 38-46.
87. Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 1975; 72: 1848-51.
88. Goodwin JS, Ceuppens JL. Regulation of immune response by prsotaglandins. J Clin Immunol 1983; 3: 295-315.
89. Brunda MJ, Herberman RM, Holden HT. Inhibition of murine naturall killer cell activity by prostaglandins. J Immunol 1980; 124: 2682-88.
90. Kunkel SL, Wiggins RC, Chensue SW, Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 1986; 137: 404-10.
91. Kambayahi T, Alexander AR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995; 154: 2283-90.
92. Pak CC, Fidler IJ. Molecular mechanisms for activated macrophage recognition of tumor cells. Semin Cancer Biol 1991; 2: 189-95.
93. Duff M, Stapleton PP, Mestre JR, et al. Cyclooxigenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon γ. Ann Surg Oncol 2003; 10: 305-13.
94. Eisengart CA, Mestre JR, Naama HA, et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol 2000; 204: 143-49.
95. Burney S, Tamir S, Gal A, et al. A mechanistic analysis of nitric oxide-induced cellular toxicity. Nitric Oxide 1997; 1: 130-44.
96. MacMicking J, Xie XQ, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
97. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-95.
98. Kirkwood JM, Schiller JH, Oken MM, et al. Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology group. J Immunotherapy 1997; 20: 146: 57.
99. Park CC, Fidler IJ. Molecular mechanisms for activated macrophage recognition of tumor cells. Semin Cancer Biol 1991; 2: 189-95.
100. Berretoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg 1986; 68: 308-12.
101. Fodstad O, Faye R, Hoifodt HK, et al. Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results Cancer Res 2001; 158: 40-50.
102. Sato S, Futakuchi M, Ogawa K, et al. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008; 99: 316: 23.
103. Giunciuglio D, Cai T, Filanti C, Manduca P, et al. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer letters 1995; 97: 69-74.
104. Sasaki A, Alcalde RE, Nishiyama A, et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction on bone resorption. Cancer Res 1998; 58: 462-7.
105. Valcarcel M, Mendoza L, Hernandez JJ, et al. Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2. J Transl Med 2011; 25; 9: 142.
106. Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of vascular endothelial growth factor by cobalt-chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cell line. Clin Exp Metastasis 1999, 17: 687-96.
107. Ono K, Akatsu T, Murakami T. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002; 17: 774-81.
108. Zerbini LF, Czibere A, Wang Y, et al. A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 2006; 66: 11922-31.
109. Marx J. Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science 2001; 291: 581-2.
110. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug: independence from COX-2 protein expression. Carcinogenesis 2001; 22: 17-25.
111. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477-86.
112. Katerinaki E, Haycock JW, Lalla R, et al. Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Melanoma Res 2006; 16: 11-22.
113. Haycock JW, Wagner M, Morandini R, Ghanem G, Rennie IG, MacNeil S. α-Melanocyte stimulating hormone inhibits NF-κB activation in human melanocytes and melanoma cells. J Invest Dermatol 1999; 113: 560-66.
114. Hedley SJ, Gawkrodger DJ, Weetman AP, et al. α-Melanocyte stimulating hormone inhibits tumour necrosis factor-α stimulated intracellular adhesion molecule-1 expression in normal cutaneous human melanocytes and in melanoma cell lines. Br J Dermatol 1998; 138: 536-43
115. Morandini R, Boeynaems JM, Hedley SJ, MacNeil S, Ghanem G. Modulation of ICAM-1 expression by α-MSH in human melanoma cells and melanocytes. J Cell Physiol 1998; 175: 276-82.
116. Zhu N, Eves PC, Katerinaki E, et al. Melanoma cell atachment, invasion and integrin expression is uregulated by tumor necrosis factor α and suppressed by α-melanocyte stimulating hormone. J Invest Dermatol 2002; 119: 1165-71.
117. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzimes. Br J Cancer 2003; 89: 1123-9.
118. Zhu N, Lalla R, Eves P, Brown TL, King A, Kemp EH, et al. Melanoma cell migration is upregulated by tumour necrosis factoralpha and suppressed by alpha-melanocyte-stimulating hormone. Br J Cancer 2004; 90: 1457-63.
119. Shaefer U, Voloshanenko O, Willen D, Walzak H. TRAIL: A multifunctional cytokine. Front Biosci 2007; 12: 3813-24.
120. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligan 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-30.
121. Ivanov VN, Partridge MA, Huang SX, Hei TK. Suppression of the Proinflamatory Response of Metastatic Melanoma Cells Increases TRAIL-Induced Apoptosis. J Cell Biochem 2011; 112: 463-75.
122. Minami S, Lum CA, Kitagawa KM, Namiki TS. Immunohistochemical expression of cyclooxygenase-2 in melanocytic skin lesions. Int J Dermatol 2011; 50: 24-9.
123. Kagoura M, Toyoda M, Matsui C, et al. Immunohistochemical study of cyclooxigenase-2 in skin cancers. J Cutan Pathol 2001; 28: 298-302.
124. Kim KH, Park EJ, Seo YJ, et al. Expression of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006;33: 319-25.
125. Denkert C, Köbel M, Berger S, et al. Expression of cyclooxigenase 2 in human malignant melanoma. Cancer Res 2001; 61: 303-8.
126. Lee C, Ramirez JA, Guitart J, Díaz LK. Expression of cycloxigenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 2008; 35: 989-94.
127. Meyer S, Vogt T, Landthaler M, Berand A, et al. Cyclooxigenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res 2009; 2009: 848645.
128. Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2: 713-8.
129. Chwirot BW, Kúzbicki Ł. Cycloxigenase-2 (COX-2): first immunhistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumors. Melanoma Res 2006; 16: 26:36.
130. Ryu HS, Chang KH, Yang HWm Kim MS, Kwom HC, Oh KS. High cyclooxigenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000; 76: 320-5.
131. Michalowski AS. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol 1994; 33: 139-57.
132. Milas L, Furuta Y, Hunter N, Nishiguchi I, Runkel S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res 1990; 50: 4473-7.
133. Furuta Y, Hunter N, Barkley T, Hall E, Milas L: Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988; 48: 3008-13.
134. Cerchietti LC, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BM. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 2005; 71: 73-81.
135. Raju H, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhacement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistics considerations. Int J Radiation Oncology Biol Phys 2002; 54: 886-94
136. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398 enhances the effect of radiation in vitro and in vivo prefferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7: 2998-3005.
137. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhacement of tumor response to radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91: 1501-4.
138. Kishi K, Petersen S, Petersen C, et al. Preferential enhacement of tumor radioresponse by a cyclooxygenase-2 inhibitor-Cancer Res 2000; 60: 1326-31.
139. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
140. Dicker AP, Williams TL, Grant DS. Trageting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001; 24: 438-42.
141. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-36.
142. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous lowdose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12-5.
143. Hermans IF, Chong TW, Palmowski MJ, et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408-13.
144. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003; 52: 377-82.
145. Jia LJ, Wei DP, Sun QM, et al. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 2007; 121: 666-74.
146. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004; 101: 2247-56.
147. Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 2009; 15: 4867-74.
148. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006; 66: 3386-91.
149. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a welltolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006; 66: 1664-74.
150. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-52.
151. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003; 52: 377-82.
152. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 2000; 60: 1878-86
153. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-24
154. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-206.
155. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous lowdose anti angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12-5.
156. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
157. Bhatt RS, Merchan J, Parker R, et al. A phase 2 pilot trial of lowdose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116: 1751-6.
158. Ramirez CC, Ma F, Federman DG, Kirsner RS. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 2005; 31: 748-52
159. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81: 62-8.
160. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-6.
161. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
162. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal antiinflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 137: 1460-8.
163. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129: 2620-7.